SMMT
Income statement / Annual
Last year (2025), Summit Therapeutics Inc's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, Summit Therapeutics Inc's net income was -$1.08 B.
See Summit Therapeutics Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
01/31/2019 |
01/31/2018 |
01/31/2017 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$583.19 K |
$1.34 M |
$628.88 K |
$611.87 K |
$57.09 M |
$14.17 M |
$2.38 M |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$24.92 K
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$583.19 K
|
$1.34 M
|
$628.88 K
|
$611.87 K
|
$56.39 M
|
$14.17 M
|
$2.38 M
|
| Gross Profit Ratio |
0
|
0
|
0
|
1
|
1
|
1
|
1
|
0.99
|
1
|
1
|
| Research and Development Expenses |
$537.67 M
|
$132.42 M
|
$455.27 M
|
$43.01 M
|
$63.12 M
|
$38.96 M
|
$32.78 M
|
$49.07 M
|
$28.98 M
|
$18.95 M
|
| General & Administrative Expenses |
$556.70 M
|
$48.35 M
|
$23.74 M
|
$22.12 M
|
$17.46 M
|
$14.06 M
|
$9.29 M
|
$16.19 M
|
$11.94 M
|
$8.28 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$827.00 K
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$556.70 M
|
$48.35 M
|
$23.74 M
|
$22.12 M
|
$17.46 M
|
$14.06 M
|
$9.29 M
|
$17.01 M
|
$11.94 M
|
$8.28 M
|
| Other Expenses |
$0.00
|
-$250.34 K
|
-$785.77 K
|
-$4.92 M
|
-$15.51 M
|
-$13.49 M
|
-$18.84 M
|
-$14.41 M
|
-$917.00 K
|
$0.00
|
| Operating Expenses |
$1.09 B
|
$180.51 M
|
$478.23 M
|
$60.22 M
|
$65.07 M
|
$39.53 M
|
$23.24 M
|
$51.67 M
|
$40.00 M
|
$27.23 M
|
| Cost And Expenses |
$1.09 B
|
$180.51 M
|
$478.23 M
|
$60.22 M
|
$65.07 M
|
$39.53 M
|
$23.24 M
|
$51.70 M
|
$40.00 M
|
$27.23 M
|
| Interest Income |
$0.00
|
$13.47 M
|
$10.40 M
|
$1.51 M
|
$0.00
|
$4.00 K
|
$4.34 K
|
$5.00 K
|
$10.10 K
|
$10.00 K
|
| Interest Expense |
$0.00
|
$8.69 M
|
$16.46 M
|
$4.40 M
|
$208.30 K
|
$255.00 K
|
$32.52 K
|
$620.00 K
|
$0.00
|
$1.08 M
|
| Depreciation & Amortization |
$146.00 K
|
$71.00 K
|
$155.32 K
|
$1.04 M
|
$996.07 K
|
$1.13 M
|
$1.06 M
|
$1.95 M
|
$400.00 K
|
$58.00 K
|
| EBITDA |
-$1.08 B |
-$168.46 M |
-$69.45 M |
-$51.58 M |
-$62.74 M |
-$37.13 M |
-$21.56 M |
$11.66 M |
-$26.34 M |
-$24.80 M |
| EBITDA Ratio |
0
|
0
|
0
|
-88.45
|
-46.9
|
-59.05
|
-35.24
|
0.2
|
-1.86
|
-10.44
|
| Operating Income Ratio |
0
|
0
|
0
|
-102.25
|
-47.64
|
-61.85
|
-36.98
|
0.09
|
-1.82
|
-10.46
|
| Total Other Income/Expenses Net |
$14.84 M
|
$3.74 M
|
-$4.14 M
|
-$5.54 M
|
-$1.79 M
|
$206.94 K
|
-$1.33 M
|
$3.69 M
|
$1.91 M
|
-$854.00 K
|
| Income Before Tax |
-$1.08 B
|
-$176.77 M
|
-$482.37 M
|
-$65.17 M
|
-$65.52 M
|
-$38.69 M
|
-$23.96 M
|
$9.08 M
|
-$23.92 M
|
-$25.71 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
-111.75
|
-48.98
|
-61.52
|
-39.15
|
0.16
|
-1.69
|
-10.82
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$155.76 K
|
$29.65 K
|
-$1.79 M
|
$3.76 M
|
$4.34 M
|
| Net Income |
-$1.08 B
|
-$176.77 M
|
-$482.37 M
|
-$65.17 M
|
-$65.52 M
|
-$38.53 M
|
-$23.99 M
|
$10.87 M
|
-$20.16 M
|
-$21.37 M
|
| Net Income Ratio |
0
|
0
|
0
|
-111.75
|
-48.98
|
-61.28
|
-39.2
|
0.19
|
-1.42
|
-8.99
|
| EPS |
-1.44 |
-0.25 |
-0.78 |
-0.34 |
-0.71 |
-0.55 |
-0.73 |
0.11 |
-0.31 |
-0.35 |
| EPS Diluted |
-1.44 |
-0.25 |
-0.78 |
-0.34 |
-0.71 |
-0.56 |
-0.73 |
0.11 |
-0.31 |
-0.35 |
| Weighted Average Shares Out |
$747.70 M
|
$713.92 M
|
$619.65 M
|
$192.15 M
|
$92.24 M
|
$69.34 M
|
$32.73 M
|
$86.14 M
|
$65.03 M
|
$61.06 M
|
| Weighted Average Shares Out Diluted |
$747.70 M
|
$718.54 M
|
$619.65 M
|
$193.34 M
|
$92.24 M
|
$69.52 M
|
$32.83 M
|
$86.14 M
|
$65.43 M
|
$61.55 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
